FDA Drug Label

What the provider says

Quoted from x402 Bazaar · source record · read 2026-10-26

---

Facts and where they come from

Price

0.01 USDC per call Provider claim

Recorded value: 0.01 USDC per call.

Unit

per call

Protocol

x402, REST · transport: HTTP Provider claim

Auth

x402

Endpoint

https://fda-drugs.use.x402atlas.com/label

Source

x402 Bazaar (Coinbase CDP) · Public discovery API (provider-published records)

Last checked

Not checked by us yet — the data is as the source published it

First seen

2026-10-24

Usage

2 calls · 2 unique payers in the 30 days before 2026-10-24. Measured by the x402 Bazaar, not by us and not by the provider.

Payments and earnings

No settled payment on record. Earnings for this service are unknown — not zero. The source counts 2 calls in 30 days, which at the published price is roughly $0.02 of activity. Activity is not revenue; no charge has been reconciled for it.

Payment rails

A payment rail is where the provider asks to be paid. It is not proof that anything was paid through it. See evidence levels.

Input and output, as published

Request

{
    "method": "GET",
    "queryParams": {
        "drug": "ozempic"
    },
    "type": "http"
}

Response

{
    "example": {
        "application_numbers": [
            "NDA209637"
        ],
        "as_of": "2026-10-21T09:00:00Z",
        "brand_names": [
            "Ozempic"
        ],
        "caveat": "Prescribing information as the manufacturer or repackager filed it with FDA; the newest matching label is served. Not medical advice.",
        "drug": "ozempic",
        "effective_date": "2026-07-30",
        "generic_names": [
            "SEMAGLUTIDE"
        ],
        "label_count": 4,
        "manufacturer": "A-S Medication Solutions",
        "modified": true,
        "product_type": "human prescription drug",
        "route": [
            "SUBCUTANEOUS"
        ],
        "rxcui": [
            "2619152",
            "2619154"
        ],
        "section": "",
        "sections": {
            "adverse_reactions": {
                "chars": 18230,
                "text": "6 ADVERSE REACTIONS The following serious adverse reactions are described below or elsewhere in the prescribing information: \u2022 Risk of Thyroid C-cell Tumors [see Warnings and Precautions ( 5.1 )] \u2022 Acute Pancreatitis [see Warnings and Precautions ( 5.2) ] \u2022 Diabetic Retinopathy Complications [see Warnings and Precautions ( 5.3 )] \u2022 Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions ( 5.5 )] \u2022 Acute Kidney Injury Due to Volume Depletion [see Warnings and Precautions ( 5.6 )] \u2022 Severe Gastrointestinal Adverse Reactions [see Warnings and Precaution\u2026",
                "truncated": true
            },
            "boxed_warning": {
                "chars": 1695,
                "text": "WARNING: RISK OF THYROID C-CELL TUMORS \u2022 In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions ( 5.1 ), Nonclinical Toxicology ( 13.1 )] . \u2022 OZEMPIC is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome \u2026",
                "truncated": true
            },
            "contraindications": {
                "chars": 570,
                "text": "4 CONTRAINDICATIONS OZEMPIC is contraindicated in patients with: \u2022 A personal or family history of MTC or in patients with MEN 2 [see Warnings and Precautions ( 5.1 )] . \u2022 A serious hypersensitivity reaction to semaglutide or to any of the excipients in OZEMPIC. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with OZEMPIC [see Warnings and Precautions ( 5.8 )] . \u2022 Personal or family history of MTC or in patients with MEN 2. ( 4 ) \u2022 Serious hypersensitivity reaction to semaglutide or any of the excipients in OZEMPIC. ( 4 )",
                "truncated": false
            },
            "dosage_and_administration": {
                "chars": 2987,
                "text": "2 DOSAGE AND ADMINISTRATION \u2022 Administer once weekly at any time of day, with or without meals. ( 2.1 ) \u2022 Start at 0.25 mg once weekly. After 4 weeks, increase the dosage to 0.5 mg once weekly. ( 2.2 ) \u2022 If additional glycemic control is needed, increase the dosage to 1 mg once weekly after at least 4 weeks on the 0.5 mg dose. ( 2.2 ) \u2022 If additional glycemic control is needed, increase the dosage to 2 mg once weekly after at least 4 weeks on the 1 mg dosage. ( 2.2 ) \u2022 To reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death, increase the dosage to 1 mg o\u2026",
                "truncated": true
            },
            "drug_interactions": {
                "chars": 2279,
                "text": "7 DRUG INTERACTIONS Oral Medications : OZEMPIC delays gastric emptying. May impact absorption of concomitantly administered oral medications. Use with caution. ( 7.2 ) 7.1 Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin OZEMPIC stimulates insulin release in the presence of elevated blood glucose concentrations. Patients receiving OZEMPIC in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. When initiating OZEMPIC, consider reducing the dose of concomitantly admini\u2026",
                "truncated": true
            },
            "indications_and_usage": {
                "chars": 1037,
                "text": "1 INDICATIONS AND USAGE OZEMPIC is indicated: \u2022 as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. \u2022 to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease. \u2022 to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease. OZEMPIC is a glucagon-like peptide 1 (GLP-1) receptor agonist ind\u2026",
                "truncated": true
            },
            "warnings": {
                "chars": 13916,
                "text": "5 WARNINGS AND PRECAUTIONS \u2022 Acute Pancreatitis: Has been observed in patients treated with GLP-1 receptor agonists, including OZEMPIC. Discontinue if pancreatitis is suspected. ( 5.2 ) \u2022 Diabetic Retinopathy Complications: Has been reported in a clinical trial. Patients with a history of diabetic retinopathy should be monitored. ( 5.3 ) \u2022 Never share an OZEMPIC pen between patients , even if the needle is changed. ( 5.4 ) \u2022 Hypoglycemia: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. Reducing dose of insulin secret\u2026",
                "truncated": true
            }
        },
        "set_id": "42bdd912-2393-44c4-b7e0-47672ca28991",
        "source": {
            "citation": "Data provided by the U.S. Food and Drug Administration (https://open.fda.gov). Normalized by x402 Atlas; not the agency's verbatim record.",
            "name": "openFDA (U.S. Food and Drug Administration)",
            "url": "https://open.fda.gov"
        },
        "substances": [
            "SEMAGLUTIDE"
        ],
        "unii": [
            "53AXN4NNHX"
        ],
        "version": "1"
    },
    "type": "json"
}

Examples are the provider's own, not a call we made.

Provenance

One row per statement. “Verified” means we checked it ourselves and the finding is quoted. “Provider claim” means we read it in the provider's own record. “Not found” is a statement about our search, not proof of absence.

Endpoint checks

We have not called this endpoint yet. Until we do, everything above is what the source published — no more.

Tags

---